Pulmonary alveolar proteinosis. Report of a case
Main Article Content
Keywords
Granulocyte-Macrophage Colony-Stimulating Factor, Pulmonary Alveolar Proteinosis, Bronchoalveolar Lavage
Abstract
Background: The pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of lipoprotein material in the alveoli. It is classified as primary, secondary and congenital. The primary form, of autoimmune origin, is characterized by antibodies against granulocyte-macrophage colony stimulating factor (GM-CSF). The aim of this article is to present a case of PAP with adequate response to treatment with bronchoalveolar lavage (BAL) and GM-CSF.
Clinical case: A 28-year-old female patient who started with mild to moderate effort dyspnea, distal cyanosis and lower respiratory tract infection. We found restrictive pattern respiratory function tests, chest X-ray with bilateral nodular reticulum pattern and high-resolution tomography with ground glass image and bronchiectasis, besides video bronchoscopy with inflammatory process. The open biopsy revealed data of alveolar proteinaceous material and mononuclear infiltrate. Treatment was given with BAL and GM-CSF which was suspended by dermal reaction. The patient had a satisfactory evolution and is currently asymptomatic.
Conclusion: The present case had clinical, imaging and histological manifestations for the diagnosis of autoimmune PAP with a satisfactory response to treatment. Although PAP is a low prevalence entity, the diagnosis and therapeutic options must be taken into account, including BAL and GM-CSF, since this factor is required for surfactant factor homeostasis.
References
Sánchez-Valadez TI, Carrillo-Muñoz A, Valero-Gómez A, Martínez-Pérez S, Pérez-Rosales A, Núñez Pérez-Redondo C, et al. Proteinosis alveolar: Informe de dos casos y comentario bibliográfico. Neumol Cir Torax. 2015;74(4):271-275.Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0028- 37462015000400006&lng=es.
Salvaterra E, Campo I. Pulmonary alveolar proteinosis: from classification to therapy. Breathe (Sheff). 2020;16(2):200018. doi: 10.1183/20734735.0018-2020.
Kumar A, Abdelmalak B, Inoue Y, Culver DA. Pulmonary alveolar proteinosis in adults: Pathophysiology and clinical approach. Lancet Respir Med. 2018;6(7):554-65. doi: 10.1016/S2213-2600(18)30043-2.
Suzuki T, Trapnell BC. Pulmonary Alveolar Proteinosis Syndrome. Clin Chest Med. 2016;37(3):431-40. doi: 10.1016/j.ccm.2016.04.006.
Hadchouel A, Drummond D, Abou Taam R, Lebourgeois M, Delacourt C, de Blic J. Alveolar proteinosis of genetic origins. Eur Respir Rev. 2020;29(158):190187. doi: 10.1183/16000617.0187-2019.
Riley L, Wang T, Ataya A. Pulmonary Alveolar Proteinosis (PAP). Am J Respir Crit Care Med. 2019;200(8):16-17. doi: 10.1164/rccm.2008P16.
McCarthy C, Avetisyan R, Carey BC, Chalk C, Trapnell BC. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2018;13(1):129. doi: 10.1186/s13023-018-0846-y.
Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5(1):16. doi: 10.1038/s41572-019-0066-3.
Rodríguez-Portal JA. Tratamiento de la proteinosis alveolar primaria del adulto. Arch Bronconeumonol. 2015;51(7):344-9.
Talamoni H, Pisapia N, Cortes L, Arellano M, Wainstein E, Svetliza G, et al. Therapeutic bilateral lung lavage in an adolescent with pulmonary alveolar proteinosis. Case report. Arch Argent Pediatr. 2020;118(3):e324-28. doi: 10.5546/aap.2020.e324.
Anderson K, Carey B, Martin A, Roark C, Chalk C, Nowell-Bostic M, et al. Pulmonary alveolar proteinosis: An autoimmune disease lacking an HLA association. PLoS One. 2019;14(3):e0213179. doi: 10.1371/journal.pone.0213179.
Galhenage J, Weerasinghe B, Dilesha W, Constantine R, Gunasena B. Pulmonary alveolar proteinosis and first successful whole lung lavage in Sri Lanka: a case report. J Med Case Rep. 2017;11(1):62. doi: 10.1186/s13256-017-1218-2.
Hunter-Guevara LR, Gillespie SM, Klompas AM, Torres NE, Barbara DW. Whole-lung lavage in a patient with pulmonary alveolar proteinosis. Ann Card Anaesth. 2018;21(2):215-17. doi: 10.4103/aca.ACA_184_17.
Ul-Rehman S, Hammersley JR. Pulmonary Alveolar Proteinosis: Crazy Paving to Whole Lung Lavage. Mayo Clin Proc. 2016;91(11):1673-74. doi: 10.1016/j.mayocp.2016.07.011.
Griese M. Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. Pediatrics. 2017;140(2):e20170610. doi: 10.1542/peds.2017- 0610.
Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019;381:923-932. doi: 10.1056/NEJMoa1816216.
Yorozuya T, Ikeda K, Chiba H, Saito A, Kuronuma K, Nishikiori H, et al. Autoimmune Pulmonary Alveolar Proteinosis Diagnosed after Exposure to a Fire Extinguisher Containing Silica Powder. Intern Med. 2019;58(14):2067-72. doi: 10.2169/internalmedicine.1557-18.
Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax. 2000;55(1):67-77. doi: 10.1136/thorax.55.1.67.
Gay P, Wallaert B, Nowak S, Yserbyt J, Anevlavis S, Hermant C, et al. Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF. Respiration. 2017;93(3):198-206. doi: 10.1159/000455179.
Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, et al. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet J Rare Dis. 2016;11(1):115.
Briens E, Delaval P, Mairesse MP, Valeyre D, Wallaert B, Lazor R, et al. Proteinosis alveolar pulmonar. Rev Mal Respir. 2002;19(2):166-82.
Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis: a review and an update. Chest. 1997;111(2):460-6.
Seymour JF, Presneill JJ. Proteinosis alveolar pulmonar: progreso en los primeros 44 años. Am J Respir Crit Care Med. 2002;166(2):215-35.
Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;161(4):1143-1148.
Huisman P, Grutters JC, van den Bosch JM. Pulmonary alveolar proteinosis: a disease caused by surfactant accumulation, and new treatment with sargramostim. Ned Tijdschr Geneeskd. 2008;152(26):1450-4.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.